To read the full story, subscribe or sign in.

Pre-revenue biotech startups go public in Hong Kong under new listing rules

Feb. 27, 2018

HONG KONG – Biotech companies that have not yet generated any revenue can seek listing on the Main Board of the Hong Kong Stock Exchange (HKEX). The exchange proposed the new policy Friday as part of the effort to lure more firms to go public, bolstering Hong Kong's biotech development.

BioWorld

Free access to BioWorld coronavirus articles

BioWorld

The articles in this collection are from BioWorld’s ongoing coverage of the COVID-19 coronavirus outbreak. Note that we have added three critical tables which are...

Single dose of Pfizer vaccine not strong enough against variants, U.K. study shows

BioWorld

LONDON – A single dose of Pfizer Inc./Biontech SE’s COVID-19 vaccine does not promote a strong enough immune response to provide protection against variants of...

Today's news in brief

BioWorld

BioWorld briefs for May 10.

Next up, Novavax, after April’s vaccine woes and therapeutic failures

BioWorld

Dangerous blood clots and thrombocytopenia, rare simultaneous side effects seen with two adenoviral vector vaccines from Astrazeneca plc and Johnson & Johnson, as...

Split vote at adcom for avacopan; FDA not Hy on Chemocentryx trial setup

BioWorld

The FDA’s Arthritis Advisory Committee panelists groped through cloudy data while complaining about the design of the phase III trial for Chemocentryx Inc.’s...